Copenhagen, 2013-03-18 12:30 CET (GLOBE NEWSWIRE) --
|
Report of insider transactions No. 2/2013 |
Copenhagen, 18 March 2013 – Pursuant to the Danish Securities Trading Act, section 28a, Zealand Pharma A/S (“Zealand”) shall announce transactions in the company’s shares and related securities by executives and persons/companies closely related to them.
In this regard, Zealand announces the following transaction:
| Name: | David H. Solomon |
| Reason: | President and Chief Executive Officer |
| Issuer: | Zealand Pharma A/S |
| Type | Shares |
| ISIN code: | DK0060257814 |
| Transaction: | Purchase |
| Trading date: | 14 March 2013 |
| Market: | NASDAQ OMX København A/S |
| Amount (number of warrants): | 20,600 |
| Exercise Price: | DKK 90.9323 |
| Market value: | DKK 1,873,206.20 |
Hereafter, David H. Solomon owns 20,600 shares and 387,150 warrants in Zealand.
# # #
For further information, please contact:
David Solomon, President and Chief Executive Officer, Tel: +45 2220 6300
Hanne Leth Hillman, Vice President and Head of IR & Corporate Communication
Tel: +45 5060 3689, email: hlh@zealandpharma.com
About Zealand
Zealand Pharma A/S (“Zealand”) (NASDAQ OMX Copenhagen: ZEAL) is a biotechnology company based in Copenhagen, Denmark. Zealand specializes in the discovery, optimization and development of novel peptide drugs and has a broad and mature pipeline of drug candidates identified through its own drug discovery activities. The company’s focus lies in the field of diabetes/metabolic diseases, and its lead drug invention is lixisenatide, a once-daily GLP-1 agonist, which is licensed to Sanofi for the treatment of Type 2 diabetes. Lixisenatide is approved in Europe (February 2013) under the name of Lyxumia®, and under regulatory review in a large number of other countries globally, including in the US (NDA filed in Dec 2012) and Japan (NDA filed in June 2013).
Zealand has a partnering strategy for the development and commercialization of its products and in addition to the collaboration with Sanofi in Type 2 diabetes, the company has partnerships with Boehringer Ingelheim in diabetes/obesity, Helsinn Healthcare in chemotherapy induced diarrhea and AbbVie in acute kidney injury. For further information: www.zealandpharma.com
